Recro Pharma, Inc. (REPH) Rating Lowered to Sell at Zacks Investment Research

Recro Pharma, Inc. (NASDAQ:REPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

A number of other equities analysts have also recently weighed in on REPH. Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and cut their price target for the stock from $21.00 to $6.50 in a report on Wednesday, June 14th. Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Tuesday, July 25th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Recro Pharma has a consensus rating of “Buy” and an average target price of $12.63.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.06. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. The company had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.90 million.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/10/13/recro-pharma-inc-reph-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Recro Pharma by 14.2% in the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock valued at $4,501,000 after purchasing an additional 79,520 shares during the last quarter. OxFORD Asset Management LLP increased its stake in Recro Pharma by 364.3% in the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 159,619 shares during the last quarter. Northern Trust Corp increased its stake in Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in Recro Pharma in the first quarter valued at $1,601,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Recro Pharma in the first quarter valued at $1,601,000. Hedge funds and other institutional investors own 65.06% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acut

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

A number of other equities analysts have also recently weighed in on REPH. Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and cut their price target for the stock from $21.00 to $6.50 in a report on Wednesday, June 14th. Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Tuesday, July 25th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Recro Pharma has a consensus rating of “Buy” and an average target price of $12.63.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.06. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. The company had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.90 million.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/10/13/recro-pharma-inc-reph-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Recro Pharma by 14.2% in the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock valued at $4,501,000 after purchasing an additional 79,520 shares during the last quarter. OxFORD Asset Management LLP increased its stake in Recro Pharma by 364.3% in the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 159,619 shares during the last quarter. Northern Trust Corp increased its stake in Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in Recro Pharma in the first quarter valued at $1,601,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Recro Pharma in the first quarter valued at $1,601,000. Hedge funds and other institutional investors own 65.06% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply